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High levels of serum vitamin D are 
associated with a decreased risk of metabolic 
diseases in both men and women, but an 
increased risk for coronary artery calcification 
in Korean men
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Abstract 
Background: There are conflicting results for relationships between serum vitamin D levels and metabolic diseases. 
The aim of this study was to investigate whether serum vitamin D levels were associated with various metabolic dis‑
eases including insulin resistance (IR), metabolic syndrome (MS), fatty liver (FL), and coronary artery calcification (CAC), 
along with assessing gender differences for these relationships in Korean adults.
Methods: A total of 180,918 subjects (98,412 men and 82,506 women) who participated in a comprehensive health 
examination in the 2012–2013 period at Kangbuk Samsung Hospital, College of Medicine, Sungkyunkwan University 
were included. Serum vitamin D and metabolic markers were analyzed and CAC was estimated. Subjects were divided 
according to quartile groups of serum vitamin D. To examine the relationships of serum vitamin D to metabolic dis‑
eases and metabolic factors, multivariate logistic analysis was conducted.
Results: High levels of serum vitamin D was associated with lower ORs for MS, IR and FL both in men and women (all 
p < 0.05). For men, ORs for CAC were significantly higher in third and the highest quartile groups for serum vitamin 
D in all the analyzed models (all p < 0.05). However, women showed no significant results between serum vitamin D 
and CAC.
Conclusions: High levels of serum vitamin D were associated with lower risk of MS, IR and FL in both Korean men 
and women, but were associated with higher risk of CAC only in men, and not in women.
Keywords: Serum vitamin D, Metabolic diseases, Coronary artery calcification, Gender difference
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
It has generally been accepted that a major role of vitamin 
D is to maintain bone health by promoting the calcium 
absorption from intestine [1]. Recently, as vitamin D 
receptors are found in almost all human cells [2], diverse 
physiological roles of vitamin D besides skeletal function 
have been speculated. Accumulating data has suggested 
a potential effect of vitamin D on various chronic dis-
eases. Also vitamin D insufficiency has become a public 
health concern for people having an indoor lifestyle and 
avoiding enough to direct sunlight. A recent study has 
also suggested that vitamin D deficiency is a pandemic 
and vitamin D deficiency, defined as having serum lev-
els of lower than 20 ng/mL (50 nmol/L), was in 40.4 % of 
Europeans [3]. Previous study with data from the Korea 
National Health and Nutrition Examination Survey 
(KNHANES) reported that 48 % of Korean men and 65 % 
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of Korean women aged over 50 years had inadequate lev-
els of serum vitamin D [4]. Nevertheless, vitamin D insuf-
ficiency is still not treated as a serious concern, and there 
is a need to investigate the health benefits of vitamin D in 
preventing and combating relevant diseases.
25-Hydroxy vitamin D (here on referred to as serum 
vitamin D) is widely used as a representative marker for 
the whole body vitamin D status since it has a longer bio-
logical half-life and a higher concentration in comparison 
to 1,25-dihydroxy vitamin D, the most active form of vita-
min D, and is an indicator of both endogenous and exog-
enous vitamin D levels [5]. Numerous studies have tried 
to find a relationship between levels of serum vitamin D 
and prevalence of various metabolic diseases [6–8]. Some 
results have shown that low levels of serum vitamin D are 
associated with increasing risk of metabolic diseases such 
as obesity, hypertension (HTN), insulin resistance (IR), 
hyperlipidemia, inflammation and cardiovascular disease 
(CVD) [6–8]. Other studies, however, have failed to dem-
onstrate these benefits. As such, there is controversy as to 
whether vitamin D has a protective role for various met-
abolic diseases and vitamin D supplementation is abso-
lutely necessary. It should be noted that most previous 
studies have had the limitation of using data from a rela-
tively small number of subjects and also neglected poten-
tial gender differences and possible multiple confounding 
factors which affect serum vitamin D [6, 8]. Therefore, a 
large-scale study also considering gender differences and 
potential multiple confounding factors is required to find 
the associations between serum vitamin D levels and 
occurrence of metabolic diseases. The aim of this study 
was to examine the distribution of vitamin D levels in 
Korean adults. We also intended to investigate whether 
serum vitamin D levels were associated with diverse met-
abolic conditions such as insulin resistance, metabolic 
syndrome (MS), fatty liver (FL) and coronary artery calci-
fication (CAC) with respect to gender and using a large-
scale dataset from occupational cohort in Korean adults.
Subjects and methods
Study population
The study population consisted of individuals who par-
ticipated in a comprehensive health examination in 
2012–2013 at Kangbuk Samsung Hospital, College of 
Medicine, Sungkyunkwan University, Korea. For 80  % 
of the subjects, they had employment. Initially 248,422 
subjects were included. After excluding 67,504 subjects 
whose values for vitamin D levels were missing, a total of 
180,918 subjects (98,412 men and 82,506 women) were 
included for the final analysis (Fig.  1). In South Korea, 
employees are required to participate in annual or bian-
nual health examinations as mandated by the Industrial 
Safety and Health Law. Some subjects voluntarily pay and 
in other instances, employers pay for these health evalu-
ations. The Institutional Review Board (IRB) at Kangbuk 
Samsung Hospital approved the study, and no specific 
informed consent from the subjects was considered to be 
necessary.
Anthropometric measurements and general characteristics
Body mass index (BMI) was calculated as weight in 
kilograms divided by height in meters squared. Waist 
circumference was measured according to a standard-
ized operating protocol. Briefly, the mid point between 
the lowest rib and the superior iliac crest was identified 
in the mid-axillary line. At this point a measuring tape 
(SECA 200, circumference measuring tape) was placed 
around the abdomen, ensuring that the tape was hori-
zontal to the floor. A measurement was taken to the near-
est 0.1  cm, and at the end of a normal expiration. This 
measurement was then repeated. If the two readings var-
ied by more than 1  %, there was a computer-generated 
prompt to take a third reading. Questionnaires were used 
to ascertain information regarding alcohol consump-
tion (glasses/day), smoking (never smoked, ex-smoker, 
current smoker), and frequency of moderate activity 
or exercise per week (moderate activity was defined as 
more than 30  min activity per day that induced slight 
breathlessness).
Medical history and diagnosis
Prior history of CVD, HTN, and diabetes mellitus (DM) 
was obtained by questionnaires. HTN was defined by 
systolic blood pressure ≥140  mmHg or diastolic blood 
pressure ≥90 mmHg, or being on medication for HTN. 
DM was diagnosed according to criteria of the American 
Diabetes Association as either fasting glucose ≥126 mg/
dL, HbA1C ≥6.5  %, or use of an oral hypoglycemic 
agent. Abdominal ultrasonography (Logic Q700 MR, 
GE Healthcare, Tokyo, Japan) with a 3.5-MHz probe 
was performed for all participants by experienced clini-
cal radiologists, and FL was diagnosed on the basis of 
standard criteria including hepatorenal echo contrast, 
liver brightness and vascular blurring. Fatty infiltration 
was classified as an increase in echogenicity of the liver 
compared with that of the renal cortex where the dia-
phragm and intrahepatic vessels appeared healthy [9]. All 
computed tomography scans (CT scan) were obtained 
with a Light speed VCT XTe-64 slice MDCT scanner (GE 
Healthcare) with the same standard scanning protocol 
using 40*2.5-mm section collimation, 400  ms rotation 
time, 120 kV tube voltage, and 124 mAS (310 mA*0.4 s) 
tube current under ECG-gated dose modulation. The 
quantitative CAC scores were calculated according to the 
method described by Agatston et al. [10]. MS was defined 
by the 2009 joint interim statement of the International 
Page 3 of 13Sung et al. Cardiovasc Diabetol  (2016) 15:112 
Diabetes Federation Task Force on Epidemiology and 
Prevention criteria, with waist circumference thresholds 
of ≥90 cm for men and ≥80 cm for women that are spe-
cific for Asian populations [11]. Same criteria for waist 
circumference were used for definition of abdominal 
obesity.
Biochemical markers and serum vitamin D
Blood samples were collected after an overnight fast. 
Serum total cholesterol, triglycerides and uric acid were 
determined using an enzymatic colorimetric assay. 
Low-density lipoprotein cholesterol (LDL-C) and high-
density lipoprotein cholesterol (HDL-C) were directly 
measured using a homogeneous enzymatic colorimetric 
assay. Serum high sensitivity C-reactive protein (hs-CRP) 
was determined using a particle-enhanced immunotur-
bidimetric assay on a Modular Analytics P800 appara-
tus (Roche Diagnostics, Rotkreuz, Switzerland). Serum 
fasting glucose concentrations were measured using 
the hexokinase method on a Cobas Integra 800 appara-
tus (Roche Diagnostics). Serum insulin was measured 
using an electrochemiluminescence immunoassay on a 
Modular Analytics E170 apparatus (Roche Diagnostics). 
IR was measured using the homeostatic model assess-
ment of insulin resistance (HOMA-IR) and was obtained 
by applying the following formula: HOMA-IR =  fasting 
insulin (IU/mL) ×  fasting blood glucose (mmol/L)/22.5 
[12]. To assess serum vitamin D status, total vitamin D 
(25-OH) was measured with a competitive immuno-
assay using the Elecsys vitamin D (25-OH) total assay 
on Modular E170 immunoanalyzer (Roche, Basel, 
Switzerland).
Statistical analysis
General characteristics and prevalence of metabolic dis-
eases of the study participants were compared among 
quartile groups of serum vitamin D. Categorical vari-
ables are presented as number (%). Continuous variables 
are presented as mean (SD) or median (IQR) based on 
the distribution of the data. Differences across quartile 
groups were tested using Chi square tests or ANOVA 
tests. The distribution of continuous variables was evalu-
ated, and right-skewed variables were log transformed for 
the one-way analysis of variance. To test for linear trends, 
we included the median value of each category as a con-
tinuous variable in the regression model. To evaluate the 
associations of outcome variables and quartiles of serum 
vitamin D, we used a logistic regression model estimat-
ing the odds ratios (ORs) with 95 % confidence intervals 
(CIs) for metabolic diseases including CAC. We used two 
models to progressively adjust for potential confound-
ers. Model 1 was adjusted for age. Model 2 was adjusted 
for age, year of screening exam, center, smoking, alco-
hol, education, physical activity and season of the year. 
For CAC, Models 3 and 4 were constructed in addition 
to Models 1 and 2. Model 3 was additionally adjusted for 
HTN, DM and CVD plus Model 2, and Model 4 was addi-
tionally adjusted for BMI, SBP, glucose and LDL-C plus 
Model 3. Statistical analyses were performed with Stata 
version 11.2 (StataCorp LP, College Station, TX, USA). 
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Fig. 1 The flow diagram of this study
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All reported p values are 2-tailed, and comparisons with 
p < 0.05 were considered statistically significant.
Results
General characteristics including the metabolic markers 
of the subjects
General characteristics and metabolic markers of sub-
jects by gender are presented in Tables 1 and 2. For the 
male subjects, the mean age was 39.8 ± 8.1 years and BMI 
was 24.5 ± 3.0 kg/m2. Of the 98,412 male subjects, 39.4 % 
were obese and 42.0  % had fatty liver. When general 
characteristics and metabolic markers were compared 
according to quartile groups of serum vitamin D levels, 
most of the markers except for TG were significantly dif-
ferent (all p  <  0.05). For female subjects, the mean age 
was 38.5 ± 8.7 years and BMI was 21.7 ± 3.1 kg/m2. Of 
the 82,506 female subjects, 27.4  % showed abdominal 
obesity and 11.8  % had FL. Most of the markers except 
for systolic blood pressure (SBP), diastolic blood pressure 
(DBP), glucose and TG were significantly different among 
the quartile groups for serum vitamin D (all p < 0.05).
Distribution of serum vitamin D levels
Figure  2 indicates the distribution of serum vitamin 
D levels according to each age group in the men and 
women groups. For men, the levels of serum vitamin D 
in each age group showed a trend of increasing with age. 
Men subjects over 70 had the highest mean of serum 
vitamin D levels. In addition, the levels of serum vitamin 
D in men were higher than those of women for all age 
groups (all p < 0.05). For female subjects, women in their 
60 s showed the highest means of serum vitamin D levels. 
Figures  3 and 4 suggest the distribution of serum vita-
min D levels according to life styles and metabolic factors 
Table 1 General characteristics by quartiles of serum vitamin D levels in men (n = 98,412)
Data are expressed as mean (SD)
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, HDL-C HDL cholesterol, TG triglyceride, hs-CRP high sensitive 
C-reactive protein, DM diabetes mellitus, HTN hypertension, FL fatty liver, MS metabolic syndrome, CVD cardiovascular disease, HOMA-IR homeostasis model 
assessment of insulin resistance
a ≥20 g/day, b ≥ 3 times/week, c ≥college graduate, d data are expressed as median (IQR)
Characteristics Total subjects Quartiles of serum vitamin D levels p for trend
Q1 (<12.9 mg/dL) Q2 (12.9–16.6 mg/dL) Q3 (16.7–21.4 mg/dL) Q4 (≥21.4 mg/dL)
n = 24,650 n = 24,612 n = 24,578 n = 24,572
Age (years) 39.8 (8.1) 37.9 (7.6) 39.0 (7.7) 40.0 (7.7) 42.1 (8.8) <0.001
BMI (kg/m2) 24.5 (3.0) 24.3 (3.2) 24.5 (3.0) 24.6 (2.9) 24.5 (2.9) <0.001
Current smoker (%) 36.0 32.4 34.5 36.9 40.2 <0.001
Alcohol intake (%)a 33.2 26.0 30.8 35.7 40.4 <0.001
Regular exercise (%)b 14.4 11.3 13.3 14.9 18.0 <0.001
Higher education (%)c 85.5 86.8 87.2 85.9 82.2 <0.001
SBP (mmHg) 112.8 (11.3) 112.2 (11.1) 112.6 (11.2) 112.9 (11.2) 113.3 (11.4) <0.001
DBP (mmHg) 73.7 (9.4) 73.1 (9.3) 73.5 (9.4) 73.9 (9.4) 74.2 (9.4) <0.001
Glucose (mg/dL) 97.2 (15.1) 96.5 (15.1) 97.0 (15.0) 97.5 (15.6) 97.9 (14.7) <0.001
Insulin (μU/mL)d 5.75 (3.86–8.37) 5.92 (3.97–8.63) 5.82 (3.91–8.44) 5.77 (3.88–8.39) 5.47 (3.71–8.0) <0.001
TC (mg/dL) 199.2 (34.2) 196.3 (34.3) 199.3 (34.1) 201.0 (34.3) 200.3 (34.1) <0.001
LDL‑C (mg/dL) 126.9 (31.1) 124.5 (31.0) 127.1 (30.8) 128.6 (31.3) 127.5 (31.2) <0.001
HDL‑C (mg/dL) 52.2 (12.5) 51.5 (12.4) 51.9 (12.2) 52.4 (12.5) 53.1 (12.8) <0.001
TG (mg/dL)d 114 (80–163) 112 (79–162) 113 (81–164) 115 (82–165) 114 (81–162) 0.070
hs‑CRP (mg/L)d 0.5 (0.3–1.1) 0.5 (0.3–1.1) 0.5 (0.3–1.1) 0.5 (0.3–1.1) 0.5 (0.3–1.1) 0.013
Obesity (%) 39.4 36.2 39.9 41.3 40.4 <0.001
Abdominal obesity (%) 30.2 28.9 30.8 31.3 30.1 0.001
DM (%) 4.59 3.81 4.25 4.78 5.54 <0.001
HTN (%) 14.8 12.7 13.5 15.3 17.7 <0.001
FL (%) 42.0 42.4 42.9 42.9 39.8 <0.001
MS (%) 15.3 14.5 15.4 15.7 15.5 0.001
CVD (%) 1.19 1.00 0.98 1.21 1.56 <0.001
HOMA‑IRd 1.36 (0.90–2.03) 1.40 (0.91–2.07) 1.38 (0.90–2.05) 1.37 (0.90–2.05) 1.31 (0.86–1.97) <0.001
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in men and women subjects, respectively (all p  <  0.05 
between men and women).
Odds ratios for metabolic diseases and metabolic factors 
by quartiles of serum vitamin D
To examine the relationships of serum vitamin D to 
metabolic diseases and metabolic factors, multivari-
ate logistic analysis was conducted. The ORs for meta-
bolic diseases and metabolic factors by quartile groups 
of serum vitamin D are presented in Tables 3 and 4. For 
men, the ORs for HTN were significantly higher in third 
and the highest quartile group of serum vitamin D in 
Model 1 (OR 1.08, 95 % CI 1.03–1.14, OR 1.09, 95 % CI 
1.03–1.15, respectively), but these significances disap-
peared in Model 2. ORs for DM were significantly lower 
in highest quartile group only in Model 2 (OR 0.88, 95 % 
CI 0.79–0.98). ORs for FL and IR (HOMA-IR >75 percen-
tile) were also significantly lower in the highest quartile 
group for both models (OR 0.83, 95  % CI 0.80–0.86, 
OR 0.86, 95  % CI 0.83–0.90 in Model 1, OR 0.77, 95  % 
CI 0.74–0.80, OR 0.84, 95  % CI 0.80–0.87 in Model 2). 
ORs for MS were lower in third and the highest quartile 
group only in Model 2 (OR 0.92, 95 % CI 0.87–0.97, OR 
0.81, 95 % CI 0.76–0.86). ORs for abdominal obesity were 
higher in second, third and the highest quartile groups in 
Model 1, and higher in second quartile group in Model 
2. For women, the ORs for HTN were significantly lower 
in the highest quartile group of serum vitamin D in both 
models (OR 0.85, 95 % CI 0.78–0.94 in Model 1, OR 0.84, 
95 % CI 0.74–0.95 in Model 2). ORs for FL, MS and IR 
(HOMA-IR >75 percentile) were also significantly lower 
in third and the highest quartile groups in both models 
(OR 0.74, 95 % CI 0.69–0.78, OR 0.71, 95 % CI 0.65–0.78, 
OR 0.73, 95  % CI 0.69–0.77 in Model 1, OR 0.69, 95  % 
CI 0.64–0.75, OR 0.65, 95 % CI 0.58–0.73, OR 0.74, 95 % 
CI 0.69–0.78 in Model 2). However, the ORs for high 
Table 2 General characteristics by quartiles of serum vitamin D levels in women (n = 82,506)
Data are expressed as mean (SD)
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, HDL-C HDL cholesterol, TG triglyceride, hs-CRP high sensitive 
C-reactive protein, DM diabetes mellitus, HTN hypertension, FL fatty liver, MS metabolic syndrome, CVD cardiovascular disease, HOMA-IR homeostasis model 
assessment of insulin resistance
a ≥20 g/day, b ≥3 times/week, c ≥college graduate, d data are expressed as median (IQR)
Characteristics Total subjects Quartiles of serum vitamin D levels p for trend
Q1 (<9.7 mg/dL) Q2 (9.7–12.8 mg/dL) Q3 (12.8–17.2 mg/dL) Q4 (≥17.2 mg/dL)
n = 20,691 n = 20,593 n = 20,604 n = 20,618
Age (years) 38.5 (8.7) 37.8 (8.6) 37.9 (8.3) 38.3 (8.3) 40.0 (9.4) <0.001
BMI (kg/m2) 21.7 (3.1) 21.7 (3.3) 21.8 (3.2) 21.7 (3.0) 21.6 (2.8) <0.001
Current smoker (%) 2.38 2.70 2.45 2.07 2.29 0.002
Alcohol intake (%)a 6.20 5.51 6.23 6.29 6.76 <0.001
Regular exercise (%)b 12.8 10.2 11.7 13.3 16.1 <0.001
Higher education (%)c 71.6 68.4 71.1 73.3 73.8 <0.001
SBP (mmHg) 100.0 (11.0) 100.1 (10.9) 100.0 (10.9) 99.8 (10.9) 100.0 (11.2) 0.357
DBP (mmHg) 64.4 (8.5) 64.3 (8.4) 64.5 (8.5) 64.3 (8.5) 64.5 (8.6) 0.053
Glucose (mg/dL) 91.4 (11.6) 91.4 (11.9) 91.4 (11.4) 91.2 (11.2) 91.5 (11.8) 0.754
Insulin (μU/mL)d 4.81 (3.29–6.84) 4.96 (3.42–7.06) 4.92 (3.38–7.02) 4.79 (3.27–6.84) 4.55 (3.13–6.43) <0.001
TC (mg/dL) 186.9 (32.6) 184.6 (32.1) 187.0 (32.8) 187.7 (32.5) 188.6 (32.8) <0.001
LDL‑C (mg/dL) 109.3 (29.6) 107.9 (29.0) 109.5 (29.9) 109.9 (29.6) 110.1 (29.7) <0.001
HDL‑C (mg/dL) 64.3 (14.5) 63.1 (14.2) 64.1 (14.5) 64.5 (14.6) 65.4 (14.8) <0.001
TG (mg/dL)d 70 (54–95) 69 (53–95) 70 (54–95) 70 (53.5–95) 70 (54–96) 0.061
hs‑CRP (mg/L)d 0.3 (0.2–0.7) 0.3 (0.2–0.7) 0.3 (0.2–0.7) 0.3 (0.2–0.7) 0.3 (0.2–0.7) <0.001
Obesity (%) 13.0 13.7 13.7 13.1 11.3 <0.001
Abdominal obesity (%) 27.4 27.4 28.2 27.8 26.3 0.014
DM (%) 1.72 1.59 1.59 1.56 2.13 <0.001
HTN (%) 5.23 5.03 4.61 4.85 6.42 <0.001
FL (%) 11.8 12.3 11.8 11.8 11.1 0.001
MS (%) 5.6 5.8 5.8 5.4 5.2 0.001
CVD (%) 0.68 0.57 0.63 0.66 0.86 0.003
HOMA‑IRd 1.08 (0.72–1.57) 1.11 (0.75–1.62) 1.10 (0.73–1.61) 1.07 (0.71–1.57) 1.02 (0.68–1.49) <0.001
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hs-CRP (>1.0 mg/L) was higher in second and the high-
est quartile groups for both models (OR 1.08, 95  % CI 
1.03–1.14, OR 1.08, 95  % CI 1.03–1.14 in Model 1, OR 
1.09, 95 % CI 1.02–1.15, OR 1.11, 95 % CI 1.05–1.18 in 
Model 2).
Odds ratios for CAC by quartiles of serum vitamin D levels
We analyzed only for subjects who had data for CAC 
(number of men = 19,999; women = 5510) to confirm that 
relationship between serum levels of vitamin D and CAC 
(Additional file 1, Tables 5 and 6). Four models were con-
structed for logistic analysis. For men, ORs for CAC were 
significantly higher in third and the highest quartile groups 
of serum vitamin D in all models (OR 1.39, 95 % CI 1.22–
1.58, OR 1.36, 95 % CI 1.20–1.54 in Model 1, OR 1.32, 95 % 
CI 1.15–1.53, OR 1.27, 95 % CI 1.10–1.47 in Model 2, OR 
1.33, 95  % CI 1.15–1.53, OR 1.28, 95  % CI 1.11–1.48 in 
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1.08–1.46 in Model 4, respectively). For women, ORs for 
CAC were significantly lower in the highest quartile group 
only in Model 2 (OR 0.59, 95 % CI 0.39–0.97), but theses 
significances were not seen in Models 1, 3 and 4. 
Discussion
In this large occupational cohort of Korean adults, the 
levels of serum vitamin D were relatively low for all age 
groups in both men and women. We could also show 
that high levels of serum vitamin D were associated with 
lower risk of MS, IR and FL for both Korean men and 
women, but were associated with higher risk of CAC only 
in men and not in women.
As the mean of serum vitamin D at all age groups 
belonged to a range of mild vitamin D deficiency, a num-
ber of Koreans are suspected to be at high risk of vita-
min D deficiency by generally used cut point (10–20 ng/
mL) [13]. It should be stressed though that there is still 
no consensus on criteria for vitamin D deficiency or what 
the optimal levels of serum vitamin D ought to be [13]. 
This is because the effect of vitamin D levels on health 
outcomes is difficult to evaluate and the results of studies 
on vitamin D deficiency vary depending on cut point of 
low vitamin D levels and characteristics of the study pop-
ulation. Some of studies reported that intestinal calcium 
absorption could be maximally maintained even under 
the lower levels than 20 ng/mL of serum vitamin D [14, 
15]. For the Korean population, more evidence is needed 
to assess relative vitamin D deficiency and the optimal 
levels of serum vitamin D.
When we conducted a logistic analysis, the levels of 
serum vitamin D was inversely associated with ORs for 
MS, IR and FL in both men and women. This implies 
that maintaining the serum vitamin D over a certain level 
may have a protective effect on occurrence of metabolic 
diseases including MS, IR and FL. These results are con-
sistent with those of previous studies suggesting a rela-
tionship between serum vitamin D and occurrence of 
metabolic diseases [16–20]. A study with Korean post-
menopausal women reported that a low serum vitamin D 
level was significantly associated with increased presence 
of MS [16], and another study with Malay adults also 
proposed that subjects with insufficient serum vitamin 
D showed higher ORs for MS [17]. Recent meta-analysis 
concluded that vitamin D status was associated with a 
risk for MS in cross-sectional studies [18]. Similar to our 
results, accumulating data has indicated that serum vita-
min D have an inverse relationships with occurrence of 
IR, key component of MS [19, 20]. A prospective study 
of non-diabetic individuals demonstrated that serum 
vitamin D levels was inversely associated with a risk of IR 
[19], and a cross sectional study also reported the same 
results [20]. In addition, one study on severely obese sub-
jects with newly onset abnormal glucose metabolism also 
proved the potential role of vitamin D in the regulation of 
glucose metabolism [21].
In our study, the OR for DM was lower only in the 
highest vitamin D group in men subjects after adjust-
ment. Potential beneficial effects of vitamin D on the pre-
vention or cure of DM emerged as an important interest. 
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Fig. 4 The means (SD) of serum vitamin D levels according to life style and metabolic factors in women
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A large prospective study suggested that a daily supple-
ment of vitamin D with calcium reduce the incidence of 
type 2 DM in women [22]. In contrast, the recent reviews 
of studies concluded that vitamin D supplementation has 
no effect on development and treatment of type 2 DM 
[23, 24]. Woman’s Health Initiative trial also reported 
that vitamin D couldn’t reduce the incidence of type 2 
DM in healthy postmenopausal women [25]. Meanwhile, 
many studies found beneficial effects of vitamin D sup-
plementation in early life on risk of type 1 DM develop-
ment [26, 27]. Meta-analysis proved significant efficacy of 
vitamin D on type 1 DM [28].
Generally, individuals with a long-standing MS are 
also linked to a higher risk of developing FL [29]. In 
our study, FL showed similar results with MS, which 
inversely related with serum vitamin D. Meta-analysis 
suggested that patients with non-alcoholic fatty liver 
disease (NAFLD) had significantly lower levels of serum 
vitamin D and a higher likelihood of vitamin D defi-
ciency [30]. Another study on adults with normal serum 
liver enzymes also found that low serum vitamin D were 
associated with the presence of NAFLD independently 
from MS and IR [31]. Although it is difficult to explain 
the mechanism on how vitamin D can affect occurrence 
of diverse metabolic diseases and knowing that these 
group of diseases are intricately linked, plausible hypoth-
eses do exist. Low levels of vitamin D can increase para-
thyroid hormone levels (PTH), which can then reduce 
insulin sensitivity by regulating the intracellular free 
calcium concentrations [32]. Vitamin D also can affect 
IR by stimulating the expression of the insulin receptor 
[33]. We postulate that low levels of vitamin D may cause 
Table 3 ORs (95  % CIs) for  metabolic disease and  metabolic factors by  quartiles of  serum vitamin D levels in  men 
(n = 98,412)
Differences were tested using multivariate-adjusted logistic regression analysis
Model 1: adjustment for age, Model 2: adjustment for model 1 plus year of screening exam, center, smoking, alcohol, education, physical activity and season
ORs odds ratios, CIs confidence intervals, HTN hypertension, FL fatty liver, MS metabolic syndrome, CVD cardiovascular disease, HOMA-IR homeostasis model 
assessment of insulin resistance, hs-CRP high sensitive C-reactive protein
a HOMA-IR >75 percentile, b hs-CRP > 1.0 mg/L
Characteristics Quartiles of serum vitamin D levels p for trend
Q1 (< 12.9 mg/dL) Q2 (12.9–16.6 mg/dL) Q3 (16.7–21.4 mg/dL) Q4 (≥21.4 mg/dL)
n = 24,650 n = 24,612 n = 24,578 n = 24,572
HTN (%)
 Model 1 1.00 (reference) 1.00 (0.95–1.06) 1.08 (1.03–1.14) 1.09 (1.03–1.15) <0.001
 Model 2 1.00 (reference) 0.98 (0.92–1.04) 1.01 (0.96–1.07) 1.02 (0.96–1.08) 0.371
DM (%)
 Model 1 1.00 (reference) 1.03 (0.94–1.13) 1.06 (0.97–1.17) 0.96 (0.88–1.05) 0.447
 Model 2 1.00 (reference) 0.99 (0.89–1.10) 0.98 (0.88–1.09) 0.88 (0.79–0.98) 0.011
CVD (%)
 Model 1 1.00 (reference) 0.89 (0.74–1.07) 1.02 (0.86–1.21) 0.97 (0.82–1.14) 0.901
 Model 2 1.00 (reference) 0.90 (0.73–1.11) 0.99 (0.81–1.20) 0.94 (0.77–1.14) 0.742
FL (%)
 Model 1 1.00 (reference) 1.00 (0.97–1.04) 0.98 (0.95–1.02) 0.83 (0.80–0.86) <0.001
 Model 2 1.00 (reference) 0.97 (0.93–1.01) 0.92 (0.89–0.96) 0.77 (0.74–0.80) <0.001
MS (%)
 Model 1 1.00 (reference) 1.05 (0.99–1.10) 1.04 (0.99–1.09) 0.95 (0.90–1.00) 0.045
 Model 2 1.00 (reference) 0.99 (0.94–1.04) 0.92 (0.87–0.97) 0.81 (0.76–0.86) <0.001
Abdominal obesity (%)
 Model 1 1.00 (reference) 1.09 (1.05–1.13) 1.11 (1.07–1.16) 1.05 (1.01–1.09) 0.011
 Model 2 1.00 (reference) 1.07 (1.02–1.11) 1.04 (1.00–1.09) 0.96 (0.92–1.00) 0.031
HOMA‑IR (%)a
 Model 1 1.00 (reference) 0.97 (0.93–1.01) 0.97 (0.94–1.01) 0.86 (0.83–0.90) <0.001
 Model 2 1.00 (reference) 0.97 (0.93–1.01) 0.96 (0.92–1.00) 0.84 (0.80–0.87) <0.001
hs‑CRP (%)b
 Model 1 1.00 (reference) 1.00 (0.96–1.04) 1.01 (0.97–1.05) 0.99 (0.95–1.03) 0.859
 Model 2 1.00 (reference) 1.01 (0.96–1.05) 1.00 (0.96–1.04) 0.98 (0.93–1.02) 0.270
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MS induced by the IR, and then long-term MS finally 
may lead to FL. Based on the above results, since vitamin 
D seems to have a beneficial effect for MS, IR and FL, 
vitamin D status should be routinely checked and more 
active treatment should be considered for subjects with 
vitamin D insufficiency or deficiency. However, as some 
of previous studies have failed to prove the relationship 
between vitamin D and metabolic diseases and the ben-
eficial effect of vitamin D supplementation on metabolic 
diseases [34], a prospective study will be needed to con-
firm the effectiveness of vitamin D in prevention and 
possibly treatment of metabolic diseases.
We conducted a subgroup analysis limit for subjects 
with data for CAC. Contrary to our expectations, a 
noticeable finding was that high level of serum vitamin 
D was significantly associated with high ORs for CAC 
and only in men subjects. High level of serum vitamin 
D seems to have harmful effects on CVD in terms of 
increasing the risk of CAC. This raises the possibility that 
high level of serum vitamin D may be a promoter of vas-
cular calcification and a risk factor for subclinical athero-
sclerosis in some cases. These results are in contrast with 
the relationship of vitamin D levels for occurrence of MS, 
IR and FL in our findings. A possible explanation for an 
association between vitamin D and CAC is that vitamin 
D can elevate the absorption of calcium and phospho-
rus, and the increased calcium and phosphorus load may 
stimulate the development of vascular calcification. Sev-
eral experimental studies have shown vitamin D-asso-
ciated vascular calcification in mouse models [35–37], 
and a clinical study also suggested that increased serum 
levels of calcium and phosphate induced by vitamin D 
Table 4 ORs (95  % CIs) for  metabolic disease and  metabolic factors by  quartiles of  serum vitamin D levels in  women 
(n = 82,506)
Differences were tested using multivariate-adjusted logistic regression analysis
Model 1: adjustment for age, Model 2: adjustment for model 1 plus year of screening exam, center, smoking, alcohol, education, physical activity and season
ORs odds ratios, CIs confidence intervals, HTN hypertension, FL fatty liver, MS metabolic syndrome, CVD cardiovascular disease, HOMA-IR homeostasis model 
assessment of insulin resistance, hs-CRP high sensitive C-reactive protein
a HOMA-IR >75 percentile, b hs-CRP >1.0 mg/L
Characteristics Quartiles of serum vitamin D levels p for trend
Q1 (<9.7 mg/dL) Q2 (9.7–12.8 mg/dL) Q3 (12.8–17.2 mg/dL) Q4 (≥17.2 mg/dL)
n = 20,691 n = 20,593 n = 20,604 n = 20,618
HTN
 Model 1 1.00 (reference) 0.92 (0.83–1.02) 0.92 (0.84–1.02) 0.85 (0.78–0.94) 0.002
 Model 2 1.00 (reference) 0.88 (0.78–1.01) 0.89 (0.78–1.01) 0.84 (0.74–0.95) 0.010
DM
 Model 1 1.00 (reference) 1.03 (0.88–1.21) 0.96 (0.82–1.12) 0.95 (0.82–1.11) 0.373
 Model 2 1.00 (reference) 1.12 (0.91–1.38) 0.94 (0.76–1.16) 0.92 (0.75–1.13) 0.198
CVD
 Model 1 1.00 (reference) 1.14 (0.88–1.47) 1.15 (0.89–1.47) 1.05 (0.83–1.34) 0.767
 Model 2 1.00 (reference) 1.31 (0.92–1.85) 1.14 (0.80–1.62) 1.13 (0.80–1.59) 0.756
FL
 Model 1 1.00 (reference) 0.95 (0.89–1.01) 0.93 (0.88–0.99) 0.74 (0.69–0.78) <0.001
 Model 2 1.00 (reference) 0.93 (0.86–1.00) 0.89 (0.83–0.96) 0.69 (0.64–0.75) <0.001
MS
 Model 1 1.00 (reference) 1.01 (0.93–1.10) 0.91 (0.83–0.99) 0.71 (0.65–0.78) <0.001
 Model 2 1.00 (reference) 0.97 (0.87–1.08) 0.84 (0.76–0.94) 0.65 (0.58–0.73) <0.001
Abdominal obesity
 Model 1 1.00 (reference) 1.04 (1.00–1.09) 1.01 (0.96–1.05) 0.85 (0.81–0.89) <0.001
 Model 2 1.00 (reference) 1.06 (1.01–1.12) 1.00 (0.95–1.06) 0.86 (0.81–0.91) <0.001
HOMA‑IRa
 Model 1 1.00 (reference) 0.98 (0.94–1.03) 0.89 (0.85–0.94) 0.73 (0.69–0.77) <0.001
 Model 2 1.00 (reference) 0.97 (0.92–1.03) 0.90 (0.85–0.96) 0.74 (0.69–0.78) <0.001
hs‑CRPb
 Model 1 1.00 (reference) 1.08 (1.03–1.14) 1.05 (1.00–1.10) 1.08 (1.03–1.14) 0.009
 Model 2 1.00 (reference) 1.09 (1.02–1.15) 1.03 (0.97–1.10) 1.11 (1.05–1.18) 0.005
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supplementation may cause the vascular wall mineraliza-
tion in chronic kidney disease (CKD) patients [38]. How-
ever, previous evidences of a link between serum vitamin 
D and occurrence of CAC showed mixed results and 
were inconclusive [38–41]. Some of studies also did not 
find an evidence to suggest a link between serum vita-
min D and CAC [39, 40, 42]. Prospective study proved 
no relation of vitamin D with CVD complication in type 
1 diabetes [43]. Other studies suggested that vitamin D 
deficiency dose not predict progression of CAC [38] and 
daily supplementation of vitamin D during 12 weeks does 
not affect cardiovascular risk including vascular calcifica-
tion markers [44]. Whereas other studies revealed that 
vitamin D levels were inversely correlated with CAC [41, 
45] and that vitamin D deficiency had a significant posi-
tive association with the presence of CAC [46]. Based on 
these conflicting results, we speculate that vitamin D may 
have dual, but opposing, roles in vascular calcification 
according to levels of serum vitamin D and characteris-
tics of the subjects.
In our results, the relations of vitamin D to metabolic 
diseases may be different according to gender. An inter-
esting finding from our study is that a positive correla-
tion between vitamin D and CAC seemed to exist only in 
men, and this was not observed in women. On the con-
trary, serum vitamin D levels in women were inversely 
associated with occurrence of CAC particularly in Model 
2. Men and women seem to respond differently to vita-
min D levels regarding CAC, and this may be due to 
gender differences related to effects of vitamin D physi-
ology and CVD [47–49], and differences from hormo-
nal influences. These gender differences in our results 
Table 5 ORs (95 % CIs) for CAC by quartiles of serum vitamin D levels in men (n = 19,999)
Differences were tested using multivariate-adjusted logistic regression analysis
Model 1: adjustment for age
Model 2: adjustment for model 1 plus year of screening exam, center, smoking, alcohol, education, physical activity and season
Model 3: adjustment for model 2 plus HTN, DM and CVD
Model 4: adjustment for model 3 plus BMI, SBP, glucose and LDL-C
ORs odds ratios, CIs confidence intervals, CAC coronary artery calcification
Quartiles of serum vitamin D levels p for trend
Q1 (<13.0 mg/dL) Q2 (13.0–16.8 mg/dL) Q3 (16.8–21.5 mg/dL) Q4 (≥21.5 mg/dL)
n = 5006 n = 4994 n = 5000 n = 4999
CAC > 0
 Model 1 1.00 (reference) 1.18 (1.04–1.35) 1.39 (1.22–1.58) 1.36 (1.20–1.54) <0.001
 Model 2 1.00 (reference) 1.14 (0.98–1.32) 1.32 (1.15–1.53) 1.27 (1.10–1.47) <0.001
 Model 3 1.00 (reference) 1.14 (0.98–1.32) 1.33 (1.15–1.53) 1.28 (1.11–1.48) <0.001
 Model 4 1.00 (reference) 1.11 (0.95–1.29) 1.27 (1.10–1.47) 1.26 (1.08–1.46) 0.001
Table 6 ORs (95 % CIs) for CAC by quartiles of serum vitamin D levels in women (n = 5510)
Differences were tested using multivariate-adjusted logistic regression analysis
Model 1: adjustment for age
Model 2: adjustment for model 1 plus year of screening exam, center, smoking, alcohol, education, physical activity, season
Model 3: adjustment for model 2 plus HTN, DM, CVD
Model 4: adjustment for model 3 plus BMI, SBP, glucose, LDL-C
ORs odds ratios, CIs confidence intervals, CAC coronary artery calcification
Quartiles of serum vitamin D levels p for trend
Q1 (<9.8 mg/dL) Q2 (9.8–13.0 mg/dL) Q3 (13.0–17.6 mg/dL) Q4 (≥17.6 mg/dL)
n = 1380 n = 1378 n = 1378 n = 1374
CAC > 0
 Model 1 1.00 (reference) 1.10 (0.75–1.60) 0.75 (0.51–1.11) 0.86 (0.61–1.23) 0.181
 Model 2 1.00 (reference) 0.99 (0.61–1.62) 0.63 (0.38–1.06) 0.59 (0.36–0.97) 0.012
 Model 3 1.00 (reference) 1.07 (0.64–1.79) 0.70 (0.41–1.19) 0.69 (0.41–1.15) 0.065
 Model 4 1.00 (reference) 1.02 (0.61–1.71) 0.68 (0.40–1.17) 0.69 (0.41–1.15) 0.068
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may also be related to the fact that men have higher cir-
culating levels of vitamin D and a higher prevalence of 
CAC than women. Some studies support our assertion. 
Recent study showed gender- and age-related difference 
between vitamin D deficiency and cardiometabolic risk 
factors [50]. Proteomic study also demonstrated signifi-
cant modulation between men and women that mapped 
to pathways of vitamin D function [51].
Gender has been known to be independent predictor 
for levels of serum vitamin D. Previous investigations 
have observed that levels of serum vitamin D is higher 
in men than women, and female gender itself is one of 
the risk factors for hypovitaminosis D [48]. One pos-
sible explanation for this difference between men and 
women is that the intestinal calcium absorption may 
be more vitamin D-dependent in men than in women 
[49]. In addition, the sex hormones like estrogen which 
interact with vitamin D could be responsible for the dif-
ferences in calcium absorption under the same vitamin 
D conditions. Meanwhile, several clinical studies have 
suggested that men subjects are more likely to have 
detectable coronary calcification than women [52], and 
coronary atherosclerosis in men tends to be more asso-
ciated with calcification than similarly affected arteries 
in women [52]. Since the effect of vitamin D on subclini-
cal atherosclerosis may be different according to gender, 
optimal range of serum vitamin D to prevent subclinical 
atherosclerosis should be decided by considering gender 
differences. These results warrant further studies on the 
specified population groups according to menopause or 
andropause to ascertain the gender-related difference in 
effect of vitamin D on CAC in more detail.
Several limitations of our study should be mentioned. 
First, since this study was cross-sectionally designed, we 
couldn’t propose cause-and-effect relationships. In the 
future, a prospective study will be needed to validate the 
findings in our study. Second, our results were obtained 
in a relatively healthy occupational cohort, so the 
application of our results cannot be extended to other 
populations. Third, an experimental study should be 
conducted to support the mechanism for the potentially 
harmful effect of vitamin D on CAC. Fourth, we were 
unable to adjust for sunlight exposure, dietary factor and 
vitamin D supplementation which are important influ-
encing factors on vitamin D status. Instead of sunlight 
exposure, we used data for season as a adjustment fac-
tor to compliment this limitation. Fifth, the data might 
be underpowered due to small sample size of women 
with CAC  >  0. Finally, we couldn’t analyze subgroups 
according to menopause or andropause due to lack of 
data, although these may influence the status of vitamin 
D and metabolic diseases. Despite these limitations, our 
study has important strengths that differentiate it from 
previous studies. We used data from a large sample size 
with homogenous characteristics like relatively healthy 
young Korean adults and considered various potential 
confounding factors such as age, smoking, alcohol, edu-
cation, physical activity, season of year, and so on. Also, 
we analyzed data that allowed analysis according to gen-
der. To our knowledge, this is the first study that reports 
a positive association between vitamin D and CAC in 
Koreans men.
Conclusion
In summary, the present study suggests that high levels 
of serum vitamin D were associated with a lower risk of 
MS, IR and FL in both Korean men and women, but were 
associated with a higher risk of CAC only in men, and 
not in women.
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